FDA
-
-
-
-
-
-
-
FDA grants priority review to Belite Bio's Stargardt disease drug
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
-
-
-
-
-
-
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update
-
-
-
-
-
-
-
Belite Bio reports positive phase 3 results for Stargardt disease drug
-
-
-
-
-
-
-
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
-
-
-
-
-
-
-
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

